Document is current
Any future updates will be listed below
-
Authors
Lim, Endry H. T. http://orcid.org/0000-0002-7385-5929
Vlaar, Alexander P. J.
de Bruin, Sanne
Rückinger, Simon
Thielert, Claus
Habel, Maria
Guo, Renfeng
Burnett, Bruce P.
Dickinson, James
Brouwer, Matthijs C.
Riedemann, Niels C.
van de Beek, Diederik
,
Witzenrath, Martin
van Paassen, Pieter
Heunks, Leo M. A.
Mourvillier, Bruno
Brouwer, Matthijs C.
Tuinman, Pieter R.
Saraiva, José Francisco K.
Marx, Gernot
Lobo, Suzana M.
Boldo, Rodrigo
Simon-Campos, Jesus A.
Cornet, Alexander D.
Grebenyuk, Anastasia
Engelbrecht, Johannes M.
Mukansi, Murimisi
Jorens, Philippe G.
Zerbib, Robert
Pilz, Korinna
Riedemann, Niels C.
Bulpa, Pierre
Taccone, Fabio S.
Hermans, Greet
Diltoer, Marc
Piagnerelli, Michael
De Neve, Nikolaas
Freire, Antonio T.
Pizzol, Felipe D.
Marinho, Anna Karolina
Sato, Victor H.
Arns da Cunha, Clovis
Neuville, Mathilde
Dellamonica, Jean
Annane, Djillali
Roquilly, Antoine
Diehl, Jean Luc
Schneider, Francis
Mira, Jean Paul
Lascarrou, Jean Baptiste
Desmedt, Luc
Dupuis, Claire
Schwebel, Carole
Thiéry, Guillaume
Gründling, Matthias
Berger, Marc
Welte, Tobias
Bauer, Michael
Jaschinski, Ulrich
Matschke, Klaus
Mercado-Longoria, Roberto
Quintana, Belinda Gomez
Zamudio-Lerma, Jorge Alberto
Moreno Hoyos Abril, Juan
Aleman Marquez, Angel
Pickkers, Peter
Otterspoor, Luuk
Hercilla Vásquez, Luis
Seas Ramos, Carlos Rafael
Peña Villalobos, Alejandro
Gianella Malca, Gonzalo
Chávez, Victoria
Filimonov, Victor
Kulabukhov, Vladimir
Acharya, Pinak
Timmermans, Sjoerd A. M. E. G.
Busch, Matthias H.
van Baarle, Floor L. F.
Koning, Rutger
ter Horst, Liora
Chekrouni, Nora
van Soest, Thijs M.
Slim, Marleen A.
van Vught, Lonneke A.
van Amstel, Rombout B. E.
Olie, Sabine E.
van Zeggeren, Ingeborg E.
van de Poll, Marcel C. G.
Neukirchen, Dorothee
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct04333420 at ClinicalTrials.govDocuments that mention this clinical trial
Pharmacokinetic analysis of vilobelimab, anaphylatoxin C5a and antidrug antibodies in PANAMO: a phase 3 study in critically ill, invasively mechanically ventilated COVID-19 patients
https://doi.org/10.1186/s40635-023-00520-8
Drug treatments for covid-19: living systematic review and network meta-analysis
https://doi.org/10.1136/bmj.m2980
-
Funding
Funding for this research was provided by:
InflaRx
German Federal Government
- License Information
-
More Information
Article History
Received: 28 February 2023
Accepted: 15 May 2023
First Online: 19 June 2023
Declarations
:
: The study protocol of the phase 3 PANAMO trial was approved by the institutional review board (Amsterdam UMC, Amsterdam, Netherlands; IRB 2020_067#B2020179). The trial was approved by the institutional review boards or ethics committees and conducted according to the Declaration of Helsinki and Good Clinical Practise guidelines. Written informed consent was provided by all patients or their legally authorised representatives. In the Netherlands and Germany, deferred consent was allowed if direct informed consent of patients’ legally authorised representatives was not possible, followed by deferred patient or patients’ representatives consent (deferred proxy consent).
: Consent for publication was provided by all patients or their legally authorised representatives.
: APJV received consulting fees from InflaRx for advisory work, paid to Amsterdam UMC. SR is an employee of Metronomia Clinical Research and a contracted statistical service provider for InflaRx. CT, MH, BPB and JD are employees of InflaRx and may hold shares and/or stock options in InflaRx. RG and NCR are founders, active officers, and executive directors of the board, and hold shares and/or stock options in InflaRx. All other authors declared no competing interests for this work.
